Ultragenyx Pharmaceutical Inc
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $213,584 | $132,944 |
| Marketable debt securities | 363,625 | 614,818 |
| Accounts receivable, net | 73,390 | 40,445 |
| Inventory | 33,969 | 26,766 |
| Other assets | 47,616 | 68,926 |
| Total current assets | 732,184 | 883,899 |
| Property, plant, and equipment, net | 290,566 | 259,726 |
| Marketable debt securities | 199,901 | 148,970 |
| Intangible assets, net | 166,271 | 160,105 |
| Goodwill | 44,406 | 44,406 |
| Other assets | 57,685 | 48,338 |
| Total assets | $1,491,013 | $1,545,444 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $42,114 | $43,274 |
| Accrued liabilities | 196,486 | 204,678 |
| Contract liabilities | — | 1,479 |
| Lease liabilities | 12,595 | 11,779 |
| Liabilities for sales of future royalties | 29,242 | — |
| Total current liabilities | 280,437 | 261,210 |
| Lease liabilities | 30,574 | 19,814 |
| Deferred tax liabilities | 30,058 | 31,667 |
| Liabilities for sales of future royalties | 862,325 | 875,439 |
| Other liabilities | 12,205 | 4,820 |
| Total liabilities | 1,215,599 | 1,192,950 |
| Commitments and contingencies (Notes 9 and 15) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value of $0.001 per share—25,000,000 shares authorized; nil outstanding in 2023 and in 2022 | — | — |
| Common stock, par value of $0.001 per share—250,000,000 shares authorized; outstanding—82,315,590 in 2023 and 70,197,297 in 2022 | 82 | 70 |
| Treasury stock, at cost, 9,559 in 2023 and nil in 2022 | (432) | — |
| Deferred compensation obligation | 432 | — |
| Additional paid-in capital | 3,662,346 | 3,140,019 |
| Accumulated other comprehensive income (loss) | 647 | (6,573) |
| Accumulated deficit | (3,387,661) | (2,781,022) |
| Total stockholders’ equity | 275,414 | 352,494 |
| Total liabilities and stockholders’ equity | $1,491,013 | $1,545,444 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.